FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 57 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q2 2017. The put-call ratio across all filers is 21.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $93,000 | +9.4% | 27,800 | -1.1% | 0.00% | – |
Q3 2019 | $85,000 | +26.9% | 28,100 | +0.4% | 0.00% | – |
Q2 2019 | $67,000 | -36.2% | 28,000 | 0.0% | 0.00% | – |
Q1 2019 | $105,000 | +5.0% | 28,000 | +0.4% | 0.00% | – |
Q4 2018 | $100,000 | -53.5% | 27,900 | -25.6% | 0.00% | – |
Q3 2018 | $215,000 | +2.9% | 37,500 | -10.3% | 0.00% | – |
Q2 2018 | $209,000 | +5.6% | 41,800 | +8.6% | 0.00% | – |
Q1 2018 | $198,000 | -14.3% | 38,500 | 0.0% | 0.00% | – |
Q4 2017 | $231,000 | -2.1% | 38,500 | -9.4% | 0.00% | – |
Q3 2017 | $236,000 | +19.8% | 42,500 | 0.0% | 0.00% | – |
Q2 2017 | $197,000 | -7.1% | 42,500 | -46.5% | 0.00% | – |
Q1 2017 | $212,000 | -60.5% | 79,500 | +3.9% | 0.00% | -100.0% |
Q4 2016 | $537,000 | +9.1% | 76,500 | -6.6% | 0.00% | 0.0% |
Q3 2016 | $492,000 | – | 81,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DSC Advisors, L.P. | 1,667,377 | $15,440,000 | 9.38% |
GREAT POINT PARTNERS LLC | 2,769,425 | $25,645,000 | 6.54% |
Opaleye Management Inc. | 630,000 | $5,834,000 | 3.05% |
Vivo Capital, LLC | 855,000 | $7,917,000 | 2.47% |
DAFNA Capital Management LLC | 278,067 | $2,575,000 | 1.79% |
RA Capital Management | 1,820,138 | $16,854,000 | 1.74% |
SENZAR ASSET MANAGEMENT, LLC | 523,397 | $4,846,656,000 | 1.25% |
Perceptive Advisors | 1,373,284 | $12,717,000 | 0.82% |
Monashee Investment Management LLC | 225,000 | $2,084,000 | 0.73% |
NEXTHERA CAPITAL LP | 125,000 | $1,158,000 | 0.71% |